LY4395089 Clinical Trials (2026): 2 Studies for Crohn Disease & Colitis, Ulcerative
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 LY4395089 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Crohn Disease & Colitis, Ulcerative) and 120 total planned enrollment. 2 LY4395089 clinical trials are actively recruiting at 12 U.S. sites across 7 states. Most recent activity: NCT07483073 (Mar 2028).
Where to Participate: All LY4395089 Trial Sites in the U.S. (12 sites across 7 states)
Every actively recruiting LY4395089trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Biopharma Informatic, LLC | Los Angeles90035 | NCT07483073 | Map |
| FL | Ezy Medical Research | Miami Lakes33015 | NCT07483073 | Map |
| FL | Ezy Medical Research | Miami Lakes33015 | NCT07483099 | Map |
| GA | Atlanta Gastroenterology Associates - Peachtree Dunwoody | Atlanta30342 | NCT07483073 | Map |
| GA | Atlanta Gastroenterology Associates - Peachtree Dunwoody | Atlanta30342 | NCT07483099 | Map |
| KS | Cotton O'Neil Digestive Health Center | Topeka66606 | NCT07483073 | Map |
| KS | Cotton O'Neil Digestive Health Center | Topeka66606 | NCT07483099 | Map |
| MI | Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center | Wyoming49519 | NCT07483073 | Map |
| NV | Vector Clinical Trials | Las Vegas89128 | NCT07483073 | Map |
| NV | Vector Clinical Trials | Las Vegas89128 | NCT07483099 | Map |
| TX | Southern Star Research Institute | San Antonio78229 | NCT07483073 | Map |
| TX | Southern Star Research Institute | San Antonio78229 | NCT07483099 | Map |
LY4395089 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P2 | 2 | 2 |
Recruiting LY4395089 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07483073 | IIBDA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | P2 | Colitis, Ulcerative | 60 | May 2026 |
| NCT07483099 | LY3074828A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease | P2 | Crohn Disease | 60 | May 2026 |
LY4395089 clinical trials by indication
Colitis, Ulcerative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07483073 | IIBD | P2 | recruiting | A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease |
Crohn Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07483099 | LY3074828 | P2 | recruiting | A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease |
LY4395089 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| IIBD | NCT07483073 | P2 | recruiting | Colitis, Ulcerative | 60 | — |
| LY3074828 | NCT07483099 | P2 | recruiting | Crohn Disease | 60 | — |
All LY4395089 trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07483073 | IIBD | A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | P2 | recruiting | 60 | Eli Lilly and Company | May 2026 |
| NCT07483099 | LY3074828 | A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease | P2 | recruiting | 60 | Eli Lilly and Company | May 2026 |
LY4395089 clinical trials: frequently asked questions
- How many LY4395089 clinical trials are there?
- 2 LY4395089 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are LY4395089 clinical trials recruiting in 2026?
- Yes — 2 LY4395089 trials are actively recruiting in 2026, with 12 U.S. sites across 7 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is LY4395089 being studied for?
- LY4395089 is being studied for Crohn Disease, Colitis, Ulcerative. The trials are grouped by indication on this page.
- What phase is LY4395089 in?
- LY4395089 clinical trials span 2 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors LY4395089 clinical trials?
- The lead sponsor across the most LY4395089 trials is Eli Lilly and Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming LY4395089as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: